Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study

Orit Kliuk Ben Bassat*, Meir Schechter, Natalia Ashtamker, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Ayelet Grupper, Nachum Vaisman, Silviu Brill, Ofri Mosenzon

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Chronic pain is prevalent but difficult to treat in patients undergoing hemodialysis (HD). Effective and safe analgesics are limited in this patient population. Our aim in this feasibility study was to evaluate the safety of sublingual oil based medical cannabis for pain management in patients undergoing HD. Methods. In a prospective randomized, double-blind, cross-over design, patients undergoing HD with chronic pain were assigned to one of three arms: BOL-DP-o-04-WPE whole-plant extract (WPE), BOL-DP-o-04 cannabinoid extraction (API) or placebo. WPE and API contained trans-delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a 1:6 ratio (1:6, THC:CBD). Patients were treated for 8 weeks, with subsequent 2-week wash out, followed by a cross-over to a different arm. The primary endpoint was safety. Results. Eighteen patients were recruited and 15 were randomized. Three did not complete drug titration period due to adverse events (AEs) and one patient died during titration due to sepsis (WPE). Of those who completed at least one treatment period, seven patients were in the WPE arm, five in the API and nine receiving placebo. The most common AEs were sleepiness, which improved after dose reduction or patient adaptation. Most AEs were mild to moderate and resolved spontaneously. Serious AEs considered related to study drug included one episode of accidental overdose (WPE) leading to hallucinations. Liver enzymes were stable during cannabis treatment. Conclusions. Short-term medical cannabis use in patients treated with HD was generally well tolerated. The safety data supports further studies to assess the overall risk–benefit of a treatment paradigm utilizing medical cannabis to control pain in this patient population.

Original languageEnglish
Pages (from-to)701-710
Number of pages10
JournalCKJ: Clinical Kidney Journal
Volume16
Issue number4
DOIs
StatePublished - Apr 2023

Keywords

  • ESKD
  • cannabis
  • end-stage kidney disease
  • hemodialysis
  • pain

Fingerprint

Dive into the research topics of 'Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study'. Together they form a unique fingerprint.

Cite this